Verquvo (vericiguat), a drug for heart failure, has been approved by the US Food and Drug Administration. It has a novel mechanism of action which demonstrated superiority to placebo in a Phase 3 trial of 5,050 patients with symptomatic chronic heart failure and left ventricular ejection fraction of less than 45%, following a worsening heart failure event. In the trial, the drug reduced the risk of cardiovascular death or hospitalisation for heart failure, according to the developer Merck & Co Inc.
